phrykt

Whitehawk Therapeutics, Inc. (WHWK): who owns it and who trades it

As of Nov 16, 2026, WHWK insiders reported 14 open-market sales worth $2.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was David James Lennon (CEO), with $1.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Whitehawk Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns WHWK

79 funds and institutions reported WHWK shares worth $198M at the end of Q2 2026, about 92% of the company. The largest holder is Yu Fan with 10.3%.

Funds and institutions (13F) 92%Everyone else 8%

10 largest owners, by share of the company

Yu Fan10.3%
Acuta Capital Partners, LLC9.9%
QVT Financial LP9.8%
Montanova Capital, LLC9.1%
Orbimed Advisors LLC8.3%
Avoro Capital Advisors LLC6.0%
Siren, L.L.C.5.0%
KVP Capital Advisors, LP4.6%
BlackRock, Inc.4.1%
Vanguard Capital Management LLC2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Yu Fan4.86M10.30%$22.3M+135%
Acuta Capital Partners, LLC4.69M9.93%$21.5M+37%
QVT Financial LP4.62M9.78%$21.1MNo change
Montanova Capital, LLC4.30M9.11%$19.7M+16%
Orbimed Advisors LLC3.93M8.34%$18M-6%
Avoro Capital Advisors LLC2.85M6.04%$13.1MNo change
Siren, L.L.C.2.34M4.95%$10.7M+12%
KVP Capital Advisors, LP2.17M4.59%$9.9MNo change
BlackRock, Inc.1.92M4.07%$8.8M+447%
Vanguard Capital Management LLC1.39M2.94%$6.4M+6%
ADAR1 Capital Management, LLC1.34M2.84%$6.1M+944%
Acorn Capital Advisors, LLC1.14M2.41%$5.2MNo change
Stempoint Capital LP1.02M2.16%$4.7M-46%
Geode Capital Management, LLC899,7801.91%$4.1M+97%
Ally Bridge Group (NY) LLC817,9391.73%$3.7MNo change
Woodline Partners LP436,6140.93%$2M+55%
Renaissance Technologies LLC413,8220.88%$1.9M-3%
State Street Corp386,9820.82%$1.8M+141%
Millennium Management LLC380,4060.81%$1.7M+23%
Eversept Partners, LP303,3060.64%$1.4M-1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, WHWK insiders reported $0 of open-market purchases and $2.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.6M
14 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 16, 2026
Filed Apr 17, 2026

Purchases and sales by month

$2.6M$2.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 16, 2026Scott M. GiacobelloCFOSale141,600$4.13$585KForm 4
Apr 15, 2026Scott M. GiacobelloCFOSale77,000$3.86$297KForm 4
Apr 14, 2026Bryan BallSee remarksSale92,460$3.64$337KForm 4
Apr 13, 2026Bryan BallSee remarksSale26,389$3.46$91.3KForm 4
Apr 10, 2026Bryan BallSee remarksSale6,596$3.43$22.6KForm 4
Apr 9, 2026Bryan BallSee remarksSale50,000$3.57$178KForm 4
Apr 9, 2026David James LennonCEOSale14,500$3.38$49KForm 4
Apr 8, 2026David James LennonCEOSale63,945$3.40$217KForm 4
Apr 7, 2026David James LennonCEOSale94,087$3.43$323KForm 4
Apr 6, 2026David James LennonCEOSale102,395$3.51$359KForm 4
Apr 2, 2026David James LennonCEOSale26,858$3.48$93.5KForm 4
Mar 2, 2026David James LennonCEOSale5,100$3.31$16.9KForm 4
Mar 2, 2026Scott M. GiacobelloCFOSale2,594$3.31$8.6KForm 4
Mar 2, 2026Bryan BallSee remarksSale1,834$3.31$6.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David James LennonCHIEF EXECUTIVE OFFICER, Director–$1.1MApr 9, 2026
Scott M. GiacobelloCHIEF FINANCIAL OFFICER–$891KApr 16, 2026
Bryan BallSee remarks–$635KApr 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

WHWK short interest

Low short interest. 4.4% of WHWK shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went up 191%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.49M WHWK shares were sold short, 4.4% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 318,468 shares, buying them all back would take about 7.8 trading days (days to cover).

Shares short, % of all shares

4.36%May 15Oct 3010.5%

Days to cover

7.8May 15Oct 3014.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.49M4.36%-5%318,4687.8
Oct 15, 20262.62M4.60%-3%354,1517.4
Sep 30, 20262.71M4.75%-1%382,2627.1
Sep 15, 20262.73M4.78%-9%292,5599.3
Aug 31, 20262.98M5.23%-41%238,37212.5
Aug 14, 20265.03M8.83%+14%482,72910.4
Jul 31, 20264.43M9.39%+6%428,01610.3
Jul 15, 20264.18M8.86%+47%552,4437.6
Jun 30, 20262.83M6.00%+140%824,1193.4
Jun 15, 20261.18M2.50%+40%213,0935.5
May 29, 2026843,6601.79%-1%338,0232.5
May 15, 2026854,9801.81%+4%616,8891.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Whitehawk Therapeutics company events

Whitehawk Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Sep 10, 2026LeadershipThe board of directors of Whitehawk Therapeutics, Inc. increased the number of its authorized directors from nine to ten, and appointed Vijay Iyengar, M.D. to fill the newly created opening on the Board, effective September 9, 2026. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 12, 2026VoteReported shareholder vote results. Filing
  5. May 21, 2026AnnouncementWhitehawk Therapeutics, Inc. issued a press release announcing, among other things, (i) the expansion of the Company’s antibody drug conjugate pipeline through an option agreement with Hangzhou DAC Biotechnology which provides access to the linker-payload CPT113 for use in up to five additional ADC… Filing
  6. May 13, 2026AgreementWhitehawk Therapeutics, Inc. entered into a Securities Purchase Agreement with each of the purchasers named therein, pursuant to which the Company agreed to sell to the PIPE Investors (i) 4,330,866 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $3.92 per… Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Mar 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Whitehawk Therapeutics financials

Famous investors that hold WHWK

4 of the 50 well-known investors we track reported holding WHWK in their latest 13F filing. The largest position is Jim Simons's, worth $2.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026663,922$2.5M0.0%+60%
Israel Englander · Millennium ManagementQ3 2026442,900$1.7M0.0%+16%
Steve Cohen · Point72 Asset ManagementQ3 202618,012$67.7K0.0%-68%
Ken Griffin · Citadel AdvisorsQ3 202615,056$56.6K0.0%-50%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named WHWK in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Dellora Investments LP13G5.6%
Nov 16, 2026Dellora Investments LP13G5.6%
Nov 16, 2026ABG Management Ltd.13G/A0.0%
Nov 16, 2026ABG Management Ltd.13G/A0.0%
Nov 13, 2026Coastlands Capital LP13G/A6.2%
Nov 13, 2026Coastlands Capital LP13G/A6.2%

Questions about Whitehawk Therapeutics, Inc. (WHWK) stock

Who owns the most WHWK stock?

The largest reported owner of Whitehawk Therapeutics, Inc. (WHWK) is Yu Fan, with 10.3% of the company. In total, 79 funds and institutions reported holding WHWK at the end of Q2 2026, together about 92% of the shares. See the largest owners.

Are WHWK insiders buying or selling?

In the last 12 months, WHWK insiders reported no open-market purchases and 14 sales worth $2.6M. The latest trade was on Apr 16, 2026. See every trade.

What is the short interest in WHWK?

As of Oct 30, 2026, 2.49M WHWK shares were sold short, 4.4% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 318,468 shares, buying them all back would take about 7.8 trading days (days to cover). See the history.

Which famous investors hold WHWK?

4 of the 50 well-known investors we track reported WHWK in their latest 13F filing, including Jim Simons, Israel Englander, Steve Cohen. The largest position is worth $2.5M. See all holders.

Executive pay

Whitehawk Therapeutics's chief executive was paid a total of $3.4M for the year ended Dec 31, 2025. In the last 12 months, Whitehawk Therapeutics's executives and directors bought no stock on the open market and sold $2.6M.

Chief executive, total pay$3.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.